-transparent.png){kind=logo}
The expression of the BCL-2 family proteins, BCL-2, BAX, BCL(XL) and BAK have been determined in a panel of 12 human ovarian carcinoma cell lines encompassing a wide range in sensitivity to cisplatin. Whereas BAX, BCL(XL) and BAK levels did not correlate with sensitivity, there was a statistically significant inverse correlation (r = -0.81; P = 0.002) between growth inhibition by cisplatin and BCL-2 levels. In sublines possessing acquired resistance to various platinum-based drugs or across a panel of human ovarian carcinoma xenografts, there was no consistent pattern of BCL-2 expression. Two relatively sensitive lines (A2780 and CH1) have been stably transfected with bcl-2 and bcl(XL) respectively and two relatively resistant lines (A2780cisR and SKOV-3) stably transfected with bax. Overexpression of BCL-2 in A2780 cells led to resistance to cisplatin compared to the vector control when assayed at 48 h post-drug incubation but a significant increase in sensitivity at 96 h. Relative rates of apoptosis at 48- and 96-h post-cisplatin exposure mirrored the growth inhibition. There was no significant difference in sensitivity of the pair of lines by clonogenic assay. No significant changes in chemosensitivity to a variety of DNA-damaging or tubulin-interactive agents were observed in the remaining transfected lines. Taken together, these results suggest that, in human ovarian carcinoma cells, high BCL-2 levels (either naturally occurring or through gene transfection) confers a trend towards sensitivity not resistance to platinum drugs.
P J Beale, and
P Rogers, and
F Boxall, and
S Y Sharp, and
L R Kelland
January 2019,
OncoTargets and therapy,
P J Beale, and
P Rogers, and
F Boxall, and
S Y Sharp, and
L R Kelland
November 2010,
Expert opinion on investigational drugs,
P J Beale, and
P Rogers, and
F Boxall, and
S Y Sharp, and
L R Kelland
January 1993,
British journal of cancer,
P J Beale, and
P Rogers, and
F Boxall, and
S Y Sharp, and
L R Kelland
September 1998,
Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology,
P J Beale, and
P Rogers, and
F Boxall, and
S Y Sharp, and
L R Kelland
January 2005,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
P J Beale, and
P Rogers, and
F Boxall, and
S Y Sharp, and
L R Kelland
January 2012,
PloS one,
P J Beale, and
P Rogers, and
F Boxall, and
S Y Sharp, and
L R Kelland
May 1996,
Cancer research,
P J Beale, and
P Rogers, and
F Boxall, and
S Y Sharp, and
L R Kelland
August 2023,
Anticancer research,
P J Beale, and
P Rogers, and
F Boxall, and
S Y Sharp, and
L R Kelland
December 2013,
Applied immunohistochemistry & molecular morphology : AIMM,
P J Beale, and
P Rogers, and
F Boxall, and
S Y Sharp, and
L R Kelland
January 2012,
Neoplasma,
